MedTrace Logo

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

NCT01993108 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2018-06-18

Study results available
· View outcomes & findings →

Summary

The goal of this research is to understand the functioning of 'regulatory circuits' in the brain. We are also interested in how the medications methylphenidate and naltrexone affect these regulatory circuits. This research study will use a scanning technique known as functional magnetic resonance imaging (fMRI) which takes a special kind of picture of the brain that enables us to "see the brain at work". Adult participants will be given a one-time dose of either methylphenidate, naltrexone,or placebo before each fMRI scan session.

The main purpose for this research is to better understand the functioning of regulatory circuits in healthy individuals and individuals with psychiatric disorders. This research may one day help us develop better treatments for these disorders.

Conditions

  • Healthy
  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

Methylphenidate

One dose 40mgs of methylphenidate one hour before fMRI scanning.

DRUG

Naltrexone

One dose 40mgs of naltrexone one hour before fMRI scanning.

DRUG

Placebo

One dose of placebo one hour before fMRI scanning.

Sponsors & Collaborators

Principal Investigators

  • Chandra Sekhar Sripada, MD, PhD · University of Michigan

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-12-31
Completion
2017-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01993108 on ClinicalTrials.gov